share_log

Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

Moomoo 24/7 ·  Mar 28 08:49

Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Buy and maintains $20 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment